Silver Book Fact

Cost of warfarin therapy for AFib patients

In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.

Gage B, Cardinalli A, Albers G, Owens D. Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation. JAMA. 1995; 274(23): 1839-45. https://jamanetwork.com/journals/jama/fullarticle/vol/274/pg/1839

Reference

Title
Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation
Publication
JAMA
Publication Date
1995
Authors
Gage B, Cardinalli A, Albers G, Owens D
Volume & Issue
Volume 274, Issue 23
Pages
1839-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.